Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

35.44USD
22 Sep 2017
Change (% chg)

$0.49 (+1.40%)
Prev Close
$34.95
Open
$35.05
Day's High
$35.55
Day's Low
$34.76
Volume
1,094,948
Avg. Vol
1,287,598
52-wk High
$55.95
52-wk Low
$30.80

Chart for

About

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $2,574.34
Shares Outstanding(Mil.): 72.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.

Sep 20 2017

UPDATE 4-Alnylam's RNAi drug succeeds in key study, shares soar

* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse

Sep 20 2017

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

Aug 30 2017

FDA approves Medicines Co's urinary tract infection drug

The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

Aug 29 2017

BRIEF-Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations

* The Medicines Company reports second quarter 2017 business and financial results

Aug 09 2017

BRIEF-The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE

* The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE

Jul 25 2017

BRIEF-Medicines Co says commenced implementation of workforce reduction​

* Medicines Co - ‍on june 1, 2017, Medicines company commenced implementation of a workforce reduction​

Jun 02 2017

BRIEF-Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

* Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

May 19 2017

BRIEF-The Medicines Company Q1 loss per share $1.44

* The Medicines Company reports first-quarter 2017 financial results

Apr 26 2017

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

Apr 26 2017

Competitors

Earnings vs. Estimates